Assessing Genetic Risk of DKK3 and SLAMF6 in Erectile Dysfunction: A Comprehensive Analysis Based on Mendelian...

Area of Science:

• Genetics
• Urology
• Immunology

Background:

• Erectile dysfunction (ED) is a complex condition with significant health and relationship impacts.
• Current ED treatments have limitations, necessitating the exploration of novel therapeutic targets.
• Understanding the genetic and molecular underpinnings of ED is crucial for developing effective interventions.

Purpose of the Study:

• To identify key genetic factors and metabolic pathways associated with erectile dysfunction (ED) risk.
• To investigate the cellular expression patterns of ED-related genes using single-cell RNA sequencing (ScRNA-Seq).
• To identify potential therapeutic agents for ED through molecular docking.

Main Methods:

• Mendelian randomization analysis integrating expression and protein quantitative trait loci data.
• Evaluation of 1,400 plasma metabolites to assess metabolic pathway involvement in ED.
• Single-cell RNA sequencing (ScRNA-Seq) to analyze gene expression in specific cell types.
• Molecular docking to screen for potential drug candidates targeting ED-related genes.

Main Results:

• DKK3 was identified as a protective factor (OR=0.8555, p=0.0087), while SLAMF6 was associated with increased ED risk (OR=1.2613, p=0.0433).
• Metabolites like piperine and choline phosphate were found to mediate ED onset.
• ScRNA-Seq showed decreased DKK3 in endothelial/smooth muscle cells and increased SLAMF6 in T cells, indicating vascular and immune roles.
• Four small molecules (icariin, luteolin, Danshenol A, Danshenxinkun A) were identified as potential therapeutic agents.

Conclusions:

• DKK3 and SLAMF6 represent novel therapeutic targets for erectile dysfunction.
• The study provides a basis for precision medicine in ED, focusing on vascular-immune regulation.
• Further mechanistic studies and clinical validation are necessary to translate these findings into effective treatments.